{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:35:43Z","timestamp":1759336543580,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejmech.2021.113556","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T02:28:49Z","timestamp":1621909729000},"page":"113556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of peptide epoxyketones as selective immunoproteasome inhibitors"],"prefix":"10.1016","volume":"221","author":[{"given":"Xuemei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duidui","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113556_bib1","first-page":"417","article-title":"Proteasome inhibitors in cancer therapy, Nature reviews","volume":"14","author":"Manasanch","year":"2017","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ejmech.2021.113556_bib2","doi-asserted-by":"crossref","first-page":"15790","DOI":"10.1073\/pnas.1521919112","article-title":"mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy","volume":"112","author":"Zhao","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2021.113556_bib3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S proteasome: a molecular machine designed for controlled proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2021.113556_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4 A resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113556_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.7725097","article-title":"Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution","volume":"268","author":"L\u00f6we","year":"1995","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2021.113556_bib6","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1021\/acscentsci.7b00252","article-title":"The proteasome in modern drug discovery: second life of a highly valuable drug target","volume":"3","author":"Cromm","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2021.113556_bib7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","article-title":"Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity","volume":"148","author":"Huber","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.113556_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-12-397863-9.00003-1","article-title":"Immunoproteasomes: structure, function, and antigen presentation","volume":"109","author":"Ferrington","year":"2012","journal-title":"Progress in molecular biology and translational science"},{"key":"10.1016\/j.ejmech.2021.113556_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coi.2012.11.004","article-title":"The immunoproteasome in antigen processing and other immunological functions","volume":"25","author":"Basler","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejmech.2021.113556_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2009.10.009","article-title":"Thymoproteasome shapes immunocompetent repertoire of CD8+ T cells","volume":"32","author":"Nitta","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2021.113556_bib11","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.1141915","article-title":"Regulation of CD8+ T cell development by thymus-specific proteasomes","volume":"316","author":"Murata","year":"2007","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2021.113556_bib12","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Canc. Res. : Off. J. Am. Assoc. Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113556_bib13","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A\u00a0phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma, Clinical cancer research","volume":"18","author":"Alsina","year":"2012","journal-title":"Off. J. Am. Assoc. Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113556_bib14","series-title":"Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-free Survival (PFS) for Patients (Pts) with Relapsed And\/or Refractory Multiple Myeloma (RRMM)","article-title":"Ixazomib, an investigational oral proteasome inhibitor (PI)","author":"Moreau","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113556_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pharmthera.2017.09.001","article-title":"Immunoproteasome-selective and non-selective inhibitors: a promising approach for the treatment of multiple myeloma","volume":"182","author":"Ettari","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2021.113556_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.seminhematol.2012.04.003","article-title":"The immunoproteasome as a target in hematologic malignancies","volume":"49","author":"Kuhn","year":"2012","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ejmech.2021.113556_bib17","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/bloodadvances.2018016360","article-title":"An inhibitor of proteasome \u03b22 sites sensitizes myeloma cells to immunoproteasome inhibitors","volume":"2","author":"Downey-Kopyscinski","year":"2018","journal-title":"Blood advances"},{"key":"10.1016\/j.ejmech.2021.113556_bib18","doi-asserted-by":"crossref","first-page":"56726","DOI":"10.18632\/oncotarget.11059","article-title":"Comparative proteomic profiling of refractory\/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy","volume":"7","author":"Dytfeld","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113556_bib19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A\u00a0selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2021.113556_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2141.2010.08491.x","article-title":"PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in\u00a0vitro and in\u00a0vivo","volume":"152","author":"Singh","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2021.113556_bib21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ejmech.2018.12.064","article-title":"Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles","volume":"164","author":"Dong","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113556_bib22","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1021\/jm500716s","article-title":"Structure-based design of \u03b21i or \u03b25i specific inhibitors of human immunoproteasomes","volume":"57","author":"de Bruin","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113556_bib23","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1016\/j.bmc.2014.04.011","article-title":"Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from \u03b2-amino acid as proteasome inhibitors","volume":"22","author":"Zhang","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113556_bib24","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.15252\/embj.201695222","article-title":"A\u00a0humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit \u03b25i","volume":"35","author":"Huber","year":"2016","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2021.113556_bib25","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1021\/acs.jmedchem.8b01201","volume":"61","author":"Johnson","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113556_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcp.2014.02.005","article-title":"Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924","volume":"89","author":"Niewerth","year":"2014","journal-title":"Biochem. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421004050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421004050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:32:42Z","timestamp":1759329162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421004050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":26,"alternative-id":["S0223523421004050"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113556","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of peptide epoxyketones as selective immunoproteasome inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113556"}}